Page 359 - Syndipharma

Sobhan Oncology Pharmaceutical Co.

IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY

Type Product Dosage Strength Indication (FDA approved) Status
form

Gemcitabine 200 mg/ 2 ml Lung Cancer (NSCLC),
Drug Vial In Market
(Gemsiban®) 1000 mg/10 ml Pancreatic Cancer
Imatinib 100 mg
Drug Tab. Chronic Myeloid Leukemia (CML), GIST In Market
(Imakin®) 400 mg
Imatinib Under License of
Drug Cap. 100 mg Chronic Myeloid Leukemia (CML), GIST
(Imatib®) Cipla (India)
Drug Lenalidomide Cap. 10 mg Myelodysplastic Syndrome, Multiple My- In Market
eloma, Mantle Cell Lymphoma
25 mg
(Lenasob®)
Oxaliplatin 100 mg/ 20 ml
Drug Vial Colorectal Cancer In Market
(Xoplat®) 50 mg/ 10 ml
Paclitaxel 300 mg/ 50 ml Lung Cancer (NSCLC),
Drug (Paclitaxel Stra- Vial 150 mg/ 25 ml Ovarian Cancer, Breast Cancer, In Market
100 mg/ 16.7 ml
gen®) 30 mg/ 5 ml AIDs-related Kaposi’s Sarcoma
Vinblastine Hodgkin’s’ disease, Lymphoma, Testic-
Drug (Vinblastin Rich- Vial 10 mg ular Cancer, Kaposi’s Sarcoma, Mycosis Secondary pack-
ter®) fungoides aging
Under License of
Vincristine Leukemia, Rhabdomyosarcoma, Wilms’ Gedeon Richter
Drug (Vincristin Rich- Vial 1 mg tumor, Neuroblastoma, Hodgkin’s’ disease, (Hungary)
ter®) NHL.

Under Development:

Breast Cancer, Ovarian Cancer
Doxorubicin 10 mg/ 5 ml
Drug Vial AML, NHL, Coming Soon
(Adriabin®) 50 mg/ 25 ml
Hodgkin’s’ disease.
Epirubicin 10 mg/ 5 ml
Drug Vial Breast Cancer Coming Soon
(Epirubin®) 50 mg/ 25 ml
Pemetrexed 100 mg Lung Cancer (NSCLC),
Drug Vial Coming Soon
(Pemexed®) 500 mg Malignant Pleural Mesothelioma
Vinorelbine 10 mg/ ml Lung Cancer (NSCLC), Ovarian cancer
Drug Vial Coming Soon
(Sobelvin®) 50 mg/ 5 ml Breast Cancer

358